SHAANXI KANGHUI PHARMACEUTICAL CO., LTD.

Shaanxi Kanghui Pharmaceutical Co., Ltd.

603139

CNE100002XT3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
13.91 ^CNY	-0.36%		-1.42%	-25.89%

26/04	Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/03	Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback	MT

Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it has received CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.

December 14, 2021

On December 14, 2021, Hubei Kelawei Biopharmaceutical Co., Ltd. closed the transaction.

Latest news about Shaanxi Kanghui Pharmaceutical Co., Ltd.

Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback	15/03	MT
Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal	24/11	MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs	17/23/17	MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/23/29	CI
Sichuan Chunsheng Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 56.795265 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	29/22/29	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	19/22/19	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	28/22/28	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. completed the acquisition of an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership).	14/21/14	CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it has received CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	14/21/14	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. agreed to acquire an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership) for CNY 30 million.	11/21/11	CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	10/21/10	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/21/27	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	22/21/22	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	27/20/27	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. acquired 51% stake in Shandong Youbang Biochemical Technology Co., Ltd. from Lai Xinsheng for CNY 32.6 million.	24/20/24	CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	18/20/18	CI
Hubei Kelaiwei Biopharmaceutical Co., Ltd. announced that it has received funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.	31/20/31	CI
Hubei Klavi Biopharmaceutical Co., Ltd. announced that it has received CNY 50.4 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. and other investors	30/20/30	CI
Hubei Klavi Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 50.4 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. and other investors	21/20/21	CI

Chart Shaanxi Kanghui Pharmaceutical Co., Ltd.

Duration

Period

Chart Shaanxi Kanghui Pharmaceutical Co., Ltd.

More charts

SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. is principally engaged in research and development, manufacture and sales of Chinese patent medicines. The Company's main products include Kun Fu Kang capsules (tablets), Fufang Shuanghua tablets, Xiaoyin granules, Fuguigutong capsules, Zhiyao Xiaoke capsules and Fufang Qingdai perfusates. The Company distributes its products just within China domestic market.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SHAANXI KANGHUI PHARMACEUTICAL CO., LTD.	-25.89%	19Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	4.2TCr
OTSUKA HOLDINGS CO., LTD.	+22.40%	2.23TCr
SANDOZ GROUP AG	+18.48%	1.52TCr
CIPLA LIMITED	+16.12%	1.4TCr
ZYDUS LIFESCIENCES LIMITED	+45.12%	1.21TCr
ONO PHARMACEUTICAL CO., LTD.	-9.58%	679.6Cr
THE MEDICINES COMPANY	-0.05%	678.76Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	549.33Cr